Wegovy Reviews: What the Trial Data and Patient Reports Show

Do Wegovy reviews match the trial results?

The Wegovy trials give a clearer measure of how often side effects occurred than individual reviews do. In three pooled trials lasting up to 68 weeks, 2,116 adults received Wegovy 2.4 mg injection and 1,261 received placebo [2]. Nausea was reported by 44% versus 16%, diarrhea by 30% versus 16%, vomiting by 24% versus 6%, constipation by 24% versus 11%, and abdominal pain by 20% versus 10% [2]. Any gastrointestinal reaction was reported by 73% versus 47% [2]. Headache (14% versus 10%), fatigue (11% versus 5%), hair loss (3% versus 1%) and dysesthesia, an altered skin sensation such as burning or pain from touch (2% versus 1%), appear in the same table [2].

Adverse reactions led 6.8% of semaglutide-treated patients and 3.2% of placebo-treated patients to stop permanently, and the most frequent reasons were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%) [2]. In STEP 1, 4.5% of semaglutide participants and 0.8% of placebo participants stopped specifically for gastrointestinal events [1].

How much weight do people actually lose?

STEP 1 is the anchor trial: double-blind, 68 weeks, 1,961 adults with a BMI of 30 or higher (or 27 or higher with a weight-related condition) and no diabetes, randomized 2:1 to weekly semaglutide 2.4 mg or placebo plus lifestyle intervention [1]. In STEP 1, mean weight loss was 14.9% (15.3 kg) on semaglutide versus 2.4% (2.6 kg) on placebo [1]. The estimated difference in weight change was -12.4 percentage points (95% CI, -13.4 to -11.5; P<0.001) [1].

Beyond the mean, STEP 1 reported how many reached each threshold. Weight loss of at least 5% was reached by 86.4% on semaglutide versus 31.5% on placebo, at least 10% by 69.1% versus 12.0%, and at least 15% by 50.5% versus 4.9% [1].

Two factors that shift the average:

Type 2 diabetes. In STEP 2, 1,210 adults with a BMI of 27 or higher and type 2 diabetes were treated for 68 weeks. Mean weight loss was 9.6% on semaglutide 2.4 mg versus 3.4% on placebo, and at least 5% loss was reached by 68.8% versus 28.5%; gastrointestinal adverse events were 63.5% versus 34.3% [4]. The Wegovy label notes that the drug produced less weight loss in patients with type 2 diabetes than in those without [2].

Dose. The STEP UP trial randomized 1,407 adults with obesity and no diabetes to 7.2 mg (n=1,005), 2.4 mg (n=201) or placebo (n=201) for 72 weeks [5]. In STEP UP, mean weight loss was 18.7% on 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo [5]. The current Wegovy injection label allows up to 7.2 mg weekly in adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss; the pediatric maximum is 2.4 mg [2]. Side effects rose with the higher dose: nausea 39% versus 35% versus 13%, vomiting 22% versus 16% versus 6%, and dysesthesia 22% versus 6% versus 0% on 7.2 mg, 2.4 mg and placebo [2].

Why do two Wegovy reviews sound so different?

The trials already contain both experiences. In STEP 1 the range ran from people who lost at least 15% (50.5%) to people who did not reach 5% [1]. Duration of treatment is another factor: in STEP 4, adults who stayed on semaglutide 2.4 mg continued losing weight between week 20 and week 68, while those switched to placebo gained weight [6].

A review may not state which product the person received, at what dose, or for how long, which a trial table does.

What happens after the last dose?

STEP 4 was a withdrawal study. After a 20-week run-in in which participants lost a mean 10.6%, 803 adults were randomized to continue semaglutide 2.4 mg or switch to placebo for 48 weeks [6]. From week 20 to week 68, weight fell a further 7.9% in the group continuing semaglutide and rose 6.9% in the group switched to placebo, a difference of 14.8 percentage points [6].

An off-treatment extension of STEP 1 followed 327 participants for a further year. Mean loss at week 68 was 17.3% on semaglutide versus 2.0% on placebo; one year after stopping, semaglutide participants had regained 11.6 percentage points, about two-thirds of what they had lost, for a net loss of 5.6% versus 0.1% from baseline, and most cardiometabolic improvements moved back toward baseline [3].

The Wegovy label also states that semaglutide has an elimination half-life of about one week and remains in the body for roughly 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [2].

What the label warns about that reviews rarely mention

The Wegovy label carries a boxed warning for thyroid C-cell tumors. Semaglutide caused dose- and duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it causes them in humans, including medullary thyroid carcinoma, is unknown. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and the label advises counseling on symptoms such as a neck mass, trouble swallowing, shortness of breath and persistent hoarseness [2].

Other label items, with trial rates where the label gives them:

• Gallbladder disease: cholelithiasis in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2% in adult injection trials [2].
• Severe gastrointestinal reactions: 4.1% versus 0.9% [2].
• Heart rate: a mean increase of 1 to 4 beats per minute, with a rise of 20 beats per minute or more in 26% versus 16% [2].
• Hypoglycemia in a Wegovy weight-loss trial involving adults with type 2 diabetes: glucose below 54 mg/dL occurred in 6.2% taking Wegovy versus 2.5% taking placebo; the risk of low blood sugar can increase when Wegovy is used with insulin or a sulfonylurea, and adding Wegovy to insulin has not been evaluated [2].
• Pregnancy: the label states that weight loss offers no benefit in pregnancy and may cause fetal harm, that Wegovy should be discontinued when pregnancy is recognized if used for weight reduction, and that it should be stopped at least 2 months before a planned pregnancy because of the long half-life [2].

Wegovy's warning about suicidal behavior and ideation was removed in February 2026, and the current Wegovy label carries no such warning [2].

Which product was the reviewer actually taking?

A 2026 review may describe Wegovy, or it may describe a compounded semaglutide product, and a post may not say which. FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing, and it reports dosing errors with compounded injectable semaglutide, including patients measuring wrong doses and doses above the label [7].